Investitionsthese
Invests in life science companies developing biotechnology and biopharmaceutical therapeutics to drive patient benefit and generate superior returns through hands-on support in drug development and clinical impact.
Investitionsphase
Early-stage to later-stage companies
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Novel therapeutics and platforms addressing unmet patient needs in healthcare
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
k.A.
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (26)
Adam Cotton
Associate
A
Anja Koenig
Global Head of NVF
A
Anja Konig
Investor
A
Anja König
Global Head of NVF
A
Austin Walne
Partner
B
Bart Dzikowski
Investor
Beat Steffen
Managing Director
C
Christoph Meier
Investor
E
Elaine Jones
Board Member
E
Elena Battistello
Investor
F
Fiona H. Marshall
Board Member
F
Fiona Marshall
Investor
Florian Muellershausen
Managing Director
F
Florian Mullerhausen
Investor
F
Florian Müllershausen
Managing Director
H
Harry Kirsch
Investor
Laura Brass
Managing Director
Marianne Uteng
Managing Director
Mathias Frederiksen
Principal
M
Michael Gilman
Investor
M
Michael Hengartner
Investor
Michal Silverberg
Managing Director
Michelle Ma
Associate
M
Mukul Mehta
Director
S
Samantha Guinn
Analyst
S
Shreeram Aradhye
Investor
